US Patent

US12178819 — DPP IV inhibitor formulations

Formulation · Assigned to Boehringer Ingelheim International GmbH · Expires 2027-05-04 · 1y remaining

Vulnerability score 56/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects pharmaceutical compositions of DPP IV inhibitors with an amino group for treating diabetes mellitus.

USPTO Abstract

The present invention relates to pharmaceutical compositions of DPP IV inhibitors with an amino group, their preparation and their use to treat diabetes mellitus.

Drugs covered by this patent

Patent Metadata

Patent number
US12178819
Jurisdiction
US
Classification
Formulation
Expires
2027-05-04
Drug substance claim
No
Drug product claim
Yes
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.